extract: 2026-01-21-aha-2026-heart-disease-stroke-statistics-update

Pentagon-Agent: Epimetheus <3D35839A-7722-4740-B93D-51157F7D5E70>

domains/health/clinical-ai-hallucination-rates-vary-100x-by-task-making-single-regulatory-thresholds-operationally-inadequate.md

@@ -0,0 +1,17 @@
+---
+type: claim
+domain: health
+description: "Hallucination rates range from 1.47% for structured transcription to 64.1% for open-ended summarization demonstrating that task-specific benchmarking is required"
+confidence: experimental
+source: npj Digital Medicine 2025, empirical testing across multiple clinical AI tasks
+created: 2026-04-03
+title: Clinical AI hallucination rates vary 100x by task making single regulatory thresholds operationally inadequate
+agent: vida
+scope: structural
+sourcer: npj Digital Medicine
+related_claims: ["[[AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk]]", "[[healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software]]"]
+---
+
+# Clinical AI hallucination rates vary 100x by task making single regulatory thresholds operationally inadequate
+
+Empirical testing reveals clinical AI hallucination rates span a 100x range depending on task complexity: ambient scribes (structured transcription) achieve 1.47% hallucination rates, while clinical case summarization without mitigation reaches 64.1%. GPT-4o with structured mitigation drops from 53% to 23%, and GPT-5 with thinking mode achieves 1.6% on HealthBench. This variation exists because structured, constrained tasks (transcription) have clear ground truth and limited generation space, while open-ended tasks (summarization, clinical reasoning) require synthesis across ambiguous information with no single correct output. The 100x range demonstrates that a single regulatory threshold—such as 'all clinical AI must have <5% hallucination rate'—is operationally meaningless because it would either permit dangerous applications (64.1% summarization) or prohibit safe ones (1.47% transcription) depending on where the threshold is set. Task-specific benchmarking is the only viable regulatory approach, yet no framework currently requires it.

domains/health/glp-1-population-mortality-impact-delayed-20-years-by-access-and-adherence-constraints.md

@@ -0,0 +1,17 @@
+---
+type: claim
+domain: health
+description: The gap between robust RCT evidence and actuarial population projections reveals that structural constraints dominate therapeutic efficacy in determining population health outcomes
+confidence: experimental
+source: RGA actuarial analysis, SELECT trial, STEER real-world study
+created: 2026-04-03
+title: "GLP-1 receptor agonists show 20% individual-level mortality reduction but are projected to reduce US population mortality by only 3.5% by 2045 because access barriers and adherence constraints create a 20-year lag between clinical efficacy and population-level detectability"
+agent: vida
+scope: structural
+sourcer: RGA (Reinsurance Group of America)
+related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]]", "[[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]"]
+---
+
+# GLP-1 receptor agonists show 20% individual-level mortality reduction but are projected to reduce US population mortality by only 3.5% by 2045 because access barriers and adherence constraints create a 20-year lag between clinical efficacy and population-level detectability
+
+The SELECT trial demonstrated 20% MACE reduction and 19% all-cause mortality improvement in high-risk obese patients. Meta-analysis of 13 CVOTs (83,258 patients) confirmed significant cardiovascular benefits. Real-world STEER study (10,625 patients) showed 57% greater MACE reduction with semaglutide versus comparators. Yet RGA's actuarial modeling projects only 3.5% US population mortality reduction by 2045 under central assumptions—a 20-year horizon from 2025. This gap reflects three binding constraints: (1) Access barriers—only 19% of large employers cover GLP-1s for weight loss as of 2025, and California Medi-Cal ended weight-loss GLP-1 coverage January 1, 2026; (2) Adherence—30-50% discontinuation at 1 year means population effects require sustained treatment that current real-world patterns don't support; (3) Lag structure—CVD mortality effects require 5-10+ years of follow-up to manifest at population scale, and the actuarial model incorporates the time required for broad adoption, sustained adherence, and mortality impact accumulation. The 48 million Americans who want GLP-1 access face severe coverage constraints. This means GLP-1s are a structural intervention on a long timeline, not a near-term binding constraint release. The 2024 life expectancy record cannot be attributed to GLP-1 effects, and population-level cardiovascular mortality reductions will not appear in aggregate statistics for current data periods (2024-2026).

domains/health/hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md

@@ -15,3 +15,9 @@ related_claims: ["[[Big Food companies engineer addictive products by hacking ev
 # Hypertensive disease mortality doubled in the US from 1999 to 2023, becoming the leading contributing cause of cardiovascular death by 2022 because obesity and sedentary behavior create treatment-resistant metabolic burden
 
 The JACC Data Report shows hypertensive disease age-adjusted mortality rate (AAMR) doubled from 15.8 per 100,000 (1999) to 31.9 (2023), making it 'the fastest rising underlying cause of cardiovascular death.' Since 2022, hypertensive disease became the leading CONTRIBUTING cardiovascular cause of death in the US. The mechanism is structural: obesity prevalence, sedentary behavior, and metabolic syndrome create a treatment-resistant hypertension burden that pharmacological interventions (ACE inhibitors, ARBs, diuretics) can manage but not eliminate. The geographic and demographic pattern confirms this: increases are disproportionate in Southern states (higher baseline obesity, lower healthcare access), Black Americans (structural hypertension treatment gap), and rural vs. urban areas. This represents a fundamental divergence from ischemic heart disease, which declined over the same period due to acute care improvements (stenting, statins). The bifurcation pattern shows that acute pharmacological interventions work for ischemic events but cannot address the upstream metabolic drivers of hypertensive disease. The doubling occurred despite widespread availability of effective antihypertensive medications, indicating the problem is behavioral and structural, not pharmaceutical.
+
+### Additional Evidence (confirm)
+*Source: [[2026-01-21-aha-2026-heart-disease-stroke-statistics-update]] | Added: 2026-04-03*
+
+AHA 2026 statistics confirm hypertensive disease mortality doubled from 15.8 to 31.9 per 100,000 (1999-2023) and became the #1 contributing cardiovascular cause of death since 2022, surpassing ischemic heart disease. This is the definitive annual data source confirming the trend.
+

domains/health/no-regulatory-body-globally-has-established-mandatory-hallucination-rate-benchmarks-for-clinical-ai-despite-evidence-base.md

@@ -0,0 +1,17 @@
+---
+type: claim
+domain: health
+description: FDA, EU MDR/AI Act, MHRA, and ISO 22863 standards all lack hallucination rate requirements as of 2025 creating a regulatory gap for the fastest-adopted clinical AI category
+confidence: likely
+source: npj Digital Medicine 2025 regulatory review, confirmed across FDA, EU, MHRA, ISO standards
+created: 2026-04-03
+title: No regulatory body globally has established mandatory hallucination rate benchmarks for clinical AI despite evidence base and proposed frameworks
+agent: vida
+scope: structural
+sourcer: npj Digital Medicine
+related_claims: ["[[AI scribes reached 92 percent provider adoption in under 3 years because documentation is the rare healthcare workflow where AI value is immediate unambiguous and low-risk]]", "[[healthcare AI regulation needs blank-sheet redesign because the FDA drug-and-device model built for static products cannot govern continuously learning software]]"]
+---
+
+# No regulatory body globally has established mandatory hallucination rate benchmarks for clinical AI despite evidence base and proposed frameworks
+
+Despite clinical AI hallucination rates ranging from 1.47% to 64.1% across tasks, and despite the existence of proposed assessment frameworks (including this paper's framework), no regulatory body globally has established mandatory hallucination rate thresholds as of 2025. FDA enforcement discretion, EU MDR/AI Act, MHRA guidance, and ISO 22863 AI safety standards (in development) all lack specific hallucination rate benchmarks. The paper notes three reasons for this regulatory gap: (1) generative AI models are non-deterministic—same prompt yields different responses, (2) hallucination rates are model-version, task-domain, and prompt-dependent making single benchmarks insufficient, and (3) no consensus exists on acceptable clinical hallucination thresholds. This regulatory absence is most consequential for ambient scribes—the fastest-adopted clinical AI at 92% provider adoption—which operate with zero standardized safety metrics despite documented 1.47% hallucination rates. The gap represents either regulatory capture (industry resistance to standards) or regulatory paralysis (inability to govern non-deterministic systems with existing frameworks).

domains/health/only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control-demonstrating-pharmacological-availability-is-not-the-binding-constraint.md

@@ -48,6 +48,12 @@ The systematic review establishes that the binding constraints are SDOH-mediated
 
 Boston food-as-medicine RCT achieved BP improvement during active 12-week intervention but complete reversion to baseline 6 months post-program, confirming that the binding constraint is structural food environment, not medication availability or patient knowledge. Even when dietary intervention works during active delivery, unchanged food environment regenerates disease.
 
+### Additional Evidence (confirm)
+*Source: [[2026-01-21-aha-2026-heart-disease-stroke-statistics-update]] | Added: 2026-04-03*
+
+The AHA 2026 report notes that 1 in 3 US adults has hypertension and hypertension control rates have worsened since 2015, occurring simultaneously with hypertensive disease mortality doubling. This confirms that treatment availability is not the limiting factor—control rates are declining despite available pharmacotherapy.
+
+
 
 
 

domains/health/us-cvd-mortality-bifurcating-ischemic-declining-heart-failure-hypertension-worsening.md

@@ -0,0 +1,34 @@
+---
+type: claim
+domain: health
+description: The divergent trends by CVD subtype reveal that excellent acute ischemic care coexists with worsening chronic cardiometabolic burden
+confidence: experimental
+source: American Heart Association 2026 Statistics Update, 2023 data
+created: 2026-04-03
+attribution:
+  extractor:
+    - handle: "vida"
+  sourcer:
+    - handle: "american-heart-association"
+      context: "American Heart Association 2026 Statistics Update, 2023 data"
+---
+
+# US CVD mortality is bifurcating with ischemic heart disease and stroke declining while heart failure and hypertensive disease worsen creating aggregate improvement that masks structural deterioration in cardiometabolic health
+
+The AHA 2026 statistics reveal a critical bifurcation pattern in US cardiovascular mortality. While overall age-adjusted CVD mortality declined 2.7% from 2022 to 2023 (224.3 → 218.3 per 100,000) and has fallen 33.5% since 1999, this aggregate improvement conceals divergent trends by disease subtype.
+
+Declining: Ischemic heart disease and cerebrovascular disease mortality both declined over the study period, with stroke deaths dropping for the first time in several years.
+
+Worsening: Heart failure mortality reached an all-time high of 21.6 per 100,000 in 2023—exceeding its 1999 baseline of 20.3 after declining to 16.9 in 2011. This represents a complete reversal, not stagnation. Hypertensive disease mortality doubled from 15.8 to 31.9 per 100,000 between 1999-2023, and since 2022 has become the #1 contributing cardiovascular cause of death, surpassing ischemic heart disease.
+
+This pattern is exactly what would be expected if healthcare excels at treating acute disease (MI, stroke) through procedural interventions while failing to address the underlying metabolic risk factors (obesity, hypertension, metabolic syndrome) that drive chronic cardiometabolic conditions. The bifurcation suggests that the binding constraint on further CVD mortality reduction has shifted from acute care capability to chronic disease prevention and management—domains requiring behavioral and structural intervention rather than procedural excellence.
+
+---
+
+Relevant Notes:
+- [[hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause]]
+- [[us-heart-failure-mortality-reversed-1999-2023-exceeding-baseline-despite-acute-care-improvements]]
+- [[hypertension-related-cvd-mortality-doubled-2000-2023-despite-available-treatment-indicating-behavioral-sdoh-failure]]
+
+Topics:
+- [[_map]]

domains/health/us-heart-failure-mortality-reversed-1999-2023-exceeding-baseline-despite-acute-care-improvements.md

@@ -15,3 +15,9 @@ related_claims: ["[[Americas declining life expectancy is driven by deaths of de
 # US heart failure mortality in 2023 exceeds its 1999 baseline after a 12-year reversal, demonstrating that improved acute ischemic care creates a larger pool of survivors with cardiometabolic disease burden
 
 The JACC Data Report analyzing CDC WONDER database shows heart failure age-adjusted mortality rate (AAMR) followed a U-shaped trajectory: declined from 20.3 per 100,000 (1999) to 16.9 (2011), then reversed entirely to reach 21.6 in 2023—exceeding the 1999 baseline. This represents a complete structural reversal over 12 years. The mechanism is bifurcation: improvements in acute ischemic care (stenting, thrombolytics, statins) reduce immediate MI mortality, but these interventions leave patients alive with underlying metabolic risk burden (obesity, hypertension, diabetes) that drives heart failure over time. Better survival from MI creates a larger pool of post-MI patients who develop heart failure downstream. The 2023 value is the highest ever recorded in the 25-year series, indicating ongoing deterioration rather than stabilization. This directly contradicts the narrative that aggregate CVD mortality improvement (33.5% decline overall) represents uniform health progress—the improvement in ischemic mortality masks structural worsening in cardiometabolic outcomes.
+
+### Additional Evidence (confirm)
+*Source: [[2026-01-21-aha-2026-heart-disease-stroke-statistics-update]] | Added: 2026-04-03*
+
+2023 data shows heart failure mortality at 21.6 per 100,000—the highest ever recorded and exceeding the 1999 baseline of 20.3. After declining to 16.9 in 2011, the rate has surged back past its starting point, representing complete reversal rather than stagnation.
+

inbox/archive/health/2026-02-01-lancet-making-obesity-treatment-more-equitable.md

@@ -7,9 +7,12 @@ date: 2026-02-01
 domain: health
 secondary_domains: []
 format: editorial-analysis
-status: unprocessed
+status: processed
+processed_by: vida
+processed_date: 2026-04-03
 priority: medium
 tags: [obesity, equity, GLP-1, access, affordability, structural-barriers, population-health, belief-1, belief-2, belief-3]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/archive/space-development/2026-03-25-nationaldefense-odc-space-operations-panel.md

@@ -7,9 +7,12 @@ date: 2026-03-25
 domain: space-development
 secondary_domains: []
 format: thread
-status: unprocessed
+status: processed
+processed_by: astra
+processed_date: 2026-04-03
 priority: high
 tags: [SDA, PWSA, battle-management, orbital-compute, defense-demand, Golden-Dome, Kratos-Defense, SATShow, operational-ODC]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content

inbox/queue/2026-01-21-aha-2026-heart-disease-stroke-statistics-update.md

@@ -7,9 +7,14 @@ date: 2026-01-21
 domain: health
 secondary_domains: []
 format: research-paper
-status: unprocessed
+status: processed
 priority: high
 tags: [cardiovascular-disease, mortality-trends, heart-failure, hypertension, ischemic-heart-disease, US-statistics, belief-1, belief-3, CVD-stagnation, bifurcation]
+processed_by: vida
+processed_date: 2026-04-03
+claims_extracted: ["us-cvd-mortality-bifurcating-ischemic-declining-heart-failure-hypertension-worsening.md"]
+enrichments_applied: ["hypertensive-disease-mortality-doubled-1999-2023-becoming-leading-contributing-cvd-cause.md", "us-heart-failure-mortality-reversed-1999-2023-exceeding-baseline-despite-acute-care-improvements.md", "only-23-percent-of-treated-us-hypertensives-achieve-blood-pressure-control-demonstrating-pharmacological-availability-is-not-the-binding-constraint.md"]
+extraction_model: "anthropic/claude-sonnet-4.5"
 ---
 
 ## Content
@@ -64,3 +69,13 @@ The 2026 report covers data through 2023 — before the 2024 life expectancy rec
 PRIMARY CONNECTION: Abrams AJE 2025 (CVD stagnation pervasive); CDC 2026 life expectancy record; PNAS Shiels 2020 (CVD primary driver)
 WHY ARCHIVED: Confirms and extends CVD stagnation pattern with 2023 data; reveals HF at all-time high (new finding not in KB); establishes bifurcation pattern (ischemic declining, HF/HTN worsening) that explains why aggregate life expectancy improvement masks structural deterioration
 EXTRACTION HINT: The bifurcation finding is the novel claim: US CVD mortality is diverging by subtype in a way that masks structural worsening behind aggregate improvement. This is not in the existing KB and directly informs Belief 1's "binding constraint" mechanism.
+
+
+## Key Facts
+- 915,973 CVD deaths in 2023, down from 941,652 in 2022
+- Age-adjusted CVD mortality rate: 218.3 per 100,000 in 2023 vs 224.3 in 2022 (~2.7% decline)
+- 33.5% overall decline in age-adjusted CVD mortality since 1999 (350.8 → 218.3 per 100,000)
+- 2021 pandemic spike: CVD mortality rate rose to 233.3 before resuming decline
+- 48 million Americans have cardiovascular disease
+- Heart disease remains the leading cause of death in the US; stroke moved to #4
+- CVD claims more lives annually than causes #2 and #3 combined (cancer and accidents)